Search research articles
Contact Us
Filters
Showing results (61-70 of 75) with videos related to
Page
of 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 16, 2001
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer
G P Stathopoulos, D Mavroudis, N Tsavaris, et al.
Cancer Immunology, Immunotherapy : CII
|
October 24, 2000
Synergy between interleukin-2 and prothymosin alpha for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas
I F Voutsas, C N Baxevanis, A D Gritzapis, et al.
Seminars in Oncology
|
November 5, 1997
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study
D V Skarlos, G Aravantinos, P Kosmidis, et al.
Oncology Research
|
November 4, 2000
Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer
A Giatromanolaki, M I Koukourakis, G P Stathopoulos, et al.
Anticancer Research
|
April 13, 2001
Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse
A Giatromanolaki, E Sivridis, G P Stathopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study
N Androulakis, C Kourousis, M A Dimopoulos, et al.
Cancer Chemotherapy and Pharmacology
|
September 6, 2005
Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study
G P Stathopoulos, Ch Christodoulou, J Stathopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 2004
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study
G P Stathopoulos, K Syrigos, A Polyzos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2003
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer
G P Stathopoulos, S K Rigatos, M A Dimopoulos, et al.
British Journal of Cancer
|
August 16, 2006
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
G P Stathopoulos, K Syrigos, G Aravantinos, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 75) with videos related to
Sort By:
Page
of 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 16, 2001
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer
G P Stathopoulos, D Mavroudis, N Tsavaris, et al.
Cancer Immunology, Immunotherapy : CII
|
October 24, 2000
Synergy between interleukin-2 and prothymosin alpha for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas
I F Voutsas, C N Baxevanis, A D Gritzapis, et al.
Seminars in Oncology
|
November 5, 1997
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study
D V Skarlos, G Aravantinos, P Kosmidis, et al.
Oncology Research
|
November 4, 2000
Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer
A Giatromanolaki, M I Koukourakis, G P Stathopoulos, et al.
Anticancer Research
|
April 13, 2001
Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse
A Giatromanolaki, E Sivridis, G P Stathopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study
N Androulakis, C Kourousis, M A Dimopoulos, et al.
Cancer Chemotherapy and Pharmacology
|
September 6, 2005
Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study
G P Stathopoulos, Ch Christodoulou, J Stathopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 2004
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study
G P Stathopoulos, K Syrigos, A Polyzos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2003
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer
G P Stathopoulos, S K Rigatos, M A Dimopoulos, et al.
British Journal of Cancer
|
August 16, 2006
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
G P Stathopoulos, K Syrigos, G Aravantinos, et al.
Page
of 8